"The number one facial concern patients have is the eye area,12 so it is essential to consider treating the temples as part of a comprehensive treatment plan. With the approval and training-led launch ...

IRVINE, Calif., Oct. 2, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the national availability of JUVÉDERM ® VOLUMA ® XC for temple hollowing. Following its U.S.

Recognized globally for its extensive line of hyaluronic acid dermal fillers, Juvederm, offered by Med Supply Solutions, stands at the forefront of cosmetic treatments designed to combat facial aging.

At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...

IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the ...

Allergan Aesthetics, an AbbVie company, announced that the FDA has approved Juvéderm Voluma XC to treat moderate to severe temple hollowing in adults over 21 years of age. According to the company, ...

IRVINE, Calif., Jan. 18, 2023 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the highly anticipated national launch of JUVÉDERM ® VOLUX™ XC. The long-lasting ...